Lupin unveils generic version of joint pain drug PENNSAID in US
Mumbai: Global pharma major Lupin Limited today announced the launch of authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution), 2% w/w of Horizon Pharma Therapeutics in the United States.PENNSAID Topical Solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s).Diclofenac Sodium...
Mumbai: Global pharma major Lupin Limited today announced the launch of authorized generic version of PENNSAID (Diclofenac Sodium Topical Solution), 2% w/w of Horizon Pharma Therapeutics in the United States.
PENNSAID Topical Solution is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s).
Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID) had estimated annual sales of USD 509 million in the U.S. (IQVIA MAT October 2022).
Read also: Spiro Gavaris appointed as President of Lupin's US Generics Business
Medical Dialogues team had earlier reported that Lupin had received approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA), Diclofenac Sodium Topical Solution USP, 2% w/w to market a generic equivalent of Pennsaid Topical Solution, 2% w/w of Horizon Pharma Ireland DAC.
Read also: Lupin bags USFDA nod for Diclofenac Sodium Topical Solution to treat arthritic knee pain
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastrointestinal (GI), central nervous system (CNS), and women's health areas. The company invested 8.7% of its revenue on research and development in FY22.
Lupin has 15 manufacturing sites, 7 research centres and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.
Read also: Lupin unveils generic equivalent of Perforomist Inhalation Solution in US
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd